Validation of a Scoring System for Predicting Malignancy in Patients Diagnosed with Atypical Ductal Hyperplasia Using an Ultrasound-Guided Core Needle Biopsy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jisun | - |
dc.contributor.author | Han, Wonshik | - |
dc.contributor.author | Go, Eun-Young | - |
dc.contributor.author | Moon, Hyeong-Gon | - |
dc.contributor.author | Ahn, Soo Kyung | - |
dc.contributor.author | Shin, Hee-Chul | - |
dc.contributor.author | You, Jee-Man | - |
dc.contributor.author | Chang, Jung Min | - |
dc.contributor.author | Cho, Nariya | - |
dc.contributor.author | Moon, Woo Kyung | - |
dc.contributor.author | Park, In Ae | - |
dc.contributor.author | Noh, Dong-Young | - |
dc.date.available | 2019-05-29T05:33:54Z | - |
dc.date.issued | 2012-12 | - |
dc.identifier.issn | 1738-6756 | - |
dc.identifier.issn | 2092-9900 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/20005 | - |
dc.description.abstract | Purpose: The need for surgical excision in patients with ultrasound-guided core needle biopsy (CNB)-diagnosed atypical ductal hyperplasia (ADH) remains an issue of debate. The present study sought to validate a scoring system (the U score, for underestimation) that we have previously developed for predicting malignancy in CNB-diagnosed ADH. Methods: The study prospectively enrolled 85 female patients with CNB-diagnosed ADH who underwent subsequent surgical excision. Underestimation was defined as a surgical specimen having malignant foci. Results: The overall underestimation rate was 37% (31/85). Multivariate analysis showed that a clinically palpable mass, microcalcification on imaging, size >15 mm and a patient age of >= 50 years were independently associated with underestimation. When applied to the scoring system, the validation score was significant (p<0.001; area under the curve, 0.852). No patient with a U score <3.5 had an underestimated lesion. Conclusion: The present study successfully validated the efficacy of our scoring system for predicting malignancy in CNB-diagnosed ADH. A U score of <= 3.5 indicates that surgical excision may not be necessary. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN BREAST CANCER SOC | - |
dc.title | Validation of a Scoring System for Predicting Malignancy in Patients Diagnosed with Atypical Ductal Hyperplasia Using an Ultrasound-Guided Core Needle Biopsy | - |
dc.type | Article | - |
dc.identifier.doi | 10.4048/jbc.2012.15.4.407 | - |
dc.identifier.bibliographicCitation | JOURNAL OF BREAST CANCER, v.15, no.4, pp 407 - 411 | - |
dc.identifier.kciid | ART001729068 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000314196900006 | - |
dc.identifier.scopusid | 2-s2.0-84872327467 | - |
dc.citation.endPage | 411 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 407 | - |
dc.citation.title | JOURNAL OF BREAST CANCER | - |
dc.citation.volume | 15 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Breast hyperplasia | - |
dc.subject.keywordAuthor | Breast neoplasms | - |
dc.subject.keywordAuthor | Diagnostic errors | - |
dc.subject.keywordAuthor | Needle biopsy | - |
dc.subject.keywordPlus | CARCINOMA IN-SITU | - |
dc.subject.keywordPlus | SURGICAL EXCISION | - |
dc.subject.keywordPlus | BREAST | - |
dc.subject.keywordPlus | UNDERESTIMATION | - |
dc.subject.keywordPlus | SPECIMENS | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.